Article | February 15, 2018

Enhanced Cold Chain Capabilities

Source: Fisher Clinical Services
Enhanced Cold Chain Capabilities

By the end of 2020 it is estimated that eight out of the ten top selling pharmaceutical products will require cold chain logistics [Technavio “Global Pharmaceutical Logistics Market 2017 – 2021”]. In anticipation of its sponsor’s needs, Fisher Clinical Services has continued to invest in both increased capacity and capabilities throughout its global network. Along with proficient monitoring and tracking resources, Fisher Clinical Services optimizes every level of the cold chain process to ensure the security of clinical trial supplies.

An example of this optimization includes the recent introduction of a shipper return and reuse program for shipments within Europe, USA and China. Trial sponsors can benefit from high performance, lightweight systems at a significantly lower cost per use. Additionally they benefit from waste reduction due to less storage space requirements at the clinical site and less waste sent to land fill or for destruction. Find out more.